The absolute bioavailability of racemic ketamine from a novel sublingual formulation

British Journal of Clinical Pharmacology

Volumn 77, Issue 6, 2014, Pages 1011-1016

  Rolan, Paul ^a   Lim, Stephen ^b   Sunderland, Vivian ^b   Liu, Yandi ^b   Molnar, Valeria ^c  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b CURTIN UNIVERSITY   (Australia)

^c Clinical Pharmacology Consulting   (Australia)

Author keywords

bioavailability; ketamine; pharmacokinetics; sublingual

Indexed keywords

KETAMINE;

ADULT; ARTICLE; BLURRED VISION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TASTE DISORDER; VISUAL DISORDER; XEROSTOMIA; AREA UNDER THE CURVE; BIOAVAILABILITY; CHEMISTRY; MEDICINAL CHEMISTRY; STEREOISOMERISM;

ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; HUMANS; KETAMINE; MALE; STEREOISOMERISM;

EID: 84901351290     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12264     Document Type: Article

References (24)

1. Niesters M, Martini C, Dahan A,. Ketamine for chronic pain: risks and benefits. Br J Clin Pharmacol 2014; 77: 357-367.
2. Elia N, Tramèr MR,. Ketamine and postoperative pain-a quantitative systematic review of randomised trials. Pain 2005; 113: 61-70.
3. Bell RF, Dahl JB, Moore RA, Kalso EA,. Perioperative ketamine for acute postoperative pain. Cochrane Database Syst Rev 2006; (1) CD004603. doi: 10.1002/14651858.CD004603.pub2.
4. Persson J,. Ketamine in pain management. CNS Neurosci Ther 2013; 19: 396-402.
5. Visser E, Schug SA, the role of ketamine in pain management. Biomed Pharmacother 2006; 60: 341-348.
6. Martin D, Lodge D,. Ketamine acts as a non-competitive N-methyl-D-aspartate antagonist on frog spinal cord in vitro. Neuropharmacology 1985; 24: 999-1003.
7. Petrenko AB, Yamakura T, Askalany AR, Kohno T, Sakimura K, Baba H,. Effects of ketamine on acute somatic nociception in wild-type and N-methyl-D-aspartate (NMDA) receptor e1 subunit knockout mice. Neuropharmacology 2006; 50: 741-747.
8. Rodriguez-Munoz M, Sanchez-Blazquez P, Vicente-Sanchez A, Berrocoso E, Garzon J, the mu-opioid receptor and the NMDA receptor associate in PAG neurons: implications in pain control. Neuropsychopharmacology 2012; 37: 338-349.
9. Simoni SD, Schwarz AJ, O'Daly OG, Marquand AF, Brittain C, Gonzales C, Stephenson S, Williams SCR, Mehta MA,. Test-retest reliability of the BOLD pharmacological MRI response to ketamine in healthy volunteers. NeuroImage 2013; 64: 75-90.
10. Jennings PA, Cameron P, Bernard S,. Ketamine as an analgesic in the pre-hospital setting: a systematic review. Acta Anaesthesiol Scand 2011; 55: 638-643.
11. Lui F, Ng KFJ,. Adjuvant analgesics in acute pain. Expert Opin Pharmacother 2011; 12: 363-385.
12. Carr DB, Goudas LC, Denman WT, Brookoff D, Staats PS, Brennen L, Green G, Albin R, Hamilton D, Rogers MC, Firestone L, Lavin PT, Mermelstein F,. Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study. Pain 2004; 108: 17-27.
13. Ryder S, Way WL, Trevor AJ,. Comparative pharmacology of the optical isomers of ketamine. Eur J Pharmacol 1978; 49: 15-23.
14. Henthorn TK, Krejcie TC, Niemann CU, Enders-Klein C, Shanks CA, Avram MJ,. Ketamine distribution described by a recirculatory pharmacokinetic model is not stereoselective. Anesthesiology 1999; 91: 1733-1743.
15. Geisslinger G, Hering W, Thomann P, Knoll R, Kamp HD, Brune K,. Pharmacokinetics and pharmacodynamics of ketamine enantiomers in surgical patients using a stereoselective analytical method. Br J Anaesth 1993; 70: 666-671.
16. Sigtermans M, Dahan A, Mooren R, Bauer M, Kest B, Sarton E,. S(+)-ketamine effect on experimental pain and cardiac output. Anesthesiology 2009; 111: 892-903.
17. Kharasch ED, Labroo R,. Metabolism of ketamine stereoisomers by human liver microsomes. Anesthesiology 1992; 77: 1201-1207.
18. Hijazi Y, Boulieu R,. Contribution of CYP3A4, CP2B6 and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 2002; 30: 853-858.
19. Olofsen E, Noppers I, Niesters M, Kharasch E, Aarts L, Sarton E, Dahan A,. Estimation of the contribution of norketamine to ketamine-induced acute pain relief and neurocognitive impairment in healthy volunteers. Anesthesiology 2012; 117: 353-364.
20. Yanagihara Y, Ohtani M Kariya S, Uchino K, Hiraishi T, Ashizawa N, Aoyama T, Yamamura Y, Yamada Y, Iga T,. Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharm Drug Dispos 2003; 24: 37-43.
21. Chong C, Schug SA, Page-Sharp M, Jenkins B, Illett KF,. Development of a sublingual/oral formulation of ketamine for use in neuropathic pain. Clin Drug Investig 2009; 29: 317-324.
22. World Medical Association (WMA) Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. Adopted by the 18th WMA General Assembly, Helsinki, June 1964, and amended by the 52nd WMA General Assembly, Edinburgh October 7, 2000. Available at http://www.wma.net/en/ 30publications/10policies/b3/index.html (last accessed 20 September 2007).
23. European Agency for the Evaluation of Medicinal Products (EMEA). International Conference on Harmonisation-World Health Organization. Guideline for Good Clinical Practice. ICH topic E 6 (R1). Available at http://www.ema.europa.eu/pdfs/human/ich/013595en.pdf (last accessed 1 December 2009).
24. Menelaou A, Doverty M, Somogyi AA,. Development of a sensitive assay for the quantification of (S)-ketamine in plasma using HPLC with UV detection. Proc Aust Soc Clin Exp Pharmacol Toxicol 2001; 9: 82.